DEFA14A ·Filed Apr 24, 2026
Proxy solicitation materials
Actionable Insight • Neutral
Monitor for any unexpected opposition or shareholder activism at the meeting, though the board's endorsement and recent reclassification suggest a routine vote. The auditor ratification is standard practice.
Final — all horizons settled through T+60d ⚠ clustered
SANA ▼ -3.95% at T+60d
NEUTRAL call ✗ call lost -3.95% · α vs SPY -9.03% · entry $3.29 → $3.16
T+1d
-0.91%
call -0.91% · α -1.08%
$3.26
settled 5mo ago
T+5d
0.00%
call 0.00% · α -0.91%
$3.29
settled 5mo ago
T+20d
-4.26%
call -4.26% · α -8.28%
$3.15
settled 4mo ago
T+60d
-3.95%
call -3.95% · α -9.03%
$3.16
settled 2mo ago
Price Chart
Loading chart...
Executive Summary
Sana Biotechnology's board is seeking shareholder approval to elect three Class II directors and ratify the appointment of Ernst & Young as auditors. This follows a recent board reclassification to balance director classes, indicating ongoing governance adjustments.
Key Facts
- Proxy statement seeks approval for three Class II director nominees: Hans E. Bishop, Robert Nelsen, and Alise S. Reicin, M.D.
- Proposal to ratify Ernst & Young as independent auditors for 2026.
- Follows a recent board reclassification of Steven D. Harr from Class I to Class III to balance board classes.
- No other business is expected at the annual meeting.
Financial Impact
No direct financial impact disclosed; governance matters.
director_electionauditor_appointment
Risk Factors
- Potential for shareholder dissent not disclosed in the filing.
- Ernst & Young's auditor independence could be questioned if significant non-audit fees are present.
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
87% bullish (15 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-174886 |
| Document: 0001193125-26-174886-index-headers.html | 0001193125-26-174886 |
| Document: 0001193125-26-174886-index.html | 0001193125-26-174886 |
| Document: 0001193125-26-174886.txt | 0001193125-26-174886 |
10 reports for SANA
60% Hit rate best @ T+20▲ +13.50%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $3.79 $3.17 | ▼ −16.36% | ▼ −15.30% | $2.87 (−24.41%) |
Aug 10, 2026 7w ago | Press Release | $3.79 $3.17 | ▼ −16.36% | ▼ −15.30% | $2.87 (−24.41%) |
May 11, 2026 20w ago | 8-K | $3.26 $2.82 | ▼ −13.50% | ▼ −11.77% | $2.87 (−12.12%) |
May 11, 2026 20w ago | Press Release | $3.26 $2.82 | ▲ +13.50% | ▲ +11.77% | $2.87 (+12.12%) |
Apr 24, 2026 23w ago | DEFA14A | $3.29 $3.15 | ▼ −4.26% | ▼ −8.28% | $2.87 (−12.92%) |
Apr 24, 2026 23w ago | 8-K | $3.29 $3.15 | ▼ −4.26% | ▼ −8.28% | $2.87 (−12.92%) |
Apr 13, 2026 24w ago | 8-K | $3.48 $3.56 | ▲ +2.30% | ▼ −4.00% | $2.87 (−17.67%) |
Apr 13, 2026 24w ago | Press Release | $3.48 $3.56 | ▲ +2.30% | ▼ −4.00% | $2.87 (−17.67%) |
Mar 13, 2026 29w ago | Press Release | $3.36 $3.21 | ▼ −4.46% | ▼ −8.05% | $2.87 (−14.73%) |
Mar 3, 2026 30w ago | Press Release | $3.82 $3.05 | ▼ −20.16% | ▼ −15.74% | $2.87 (−25.00%) |
Showing 10 of 10
US Market Status
Market Open — Closes in 48m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access